GlobeNewswire

Cloudflare Workers Opens Edge Computing to Everyone

Dela

Industry-first solution makes Cloudflare the leader in edge computing

SAN FRANCISCO, March 13, 2018 (GLOBE NEWSWIRE) -- Cloudflare, the leading Internet performance and security company, today announced the general availability of Cloudflare Workers, a new way for developers to deploy and execute their code directly at the edge of Cloudflare's global network.

Prior to Cloudflare Workers, there were two main places where developers could deploy code: front-end code running on an end user's device, or back-end code running in a central data center. Both have their drawbacks. Code running on an end user's device is difficult to update and is limited by power and bandwidth. Code running in a central data center can have substantial network latency and be subject to outages.

Cloudflare Workers gives developers a third place  to deploy their code close to their customers - at the edge of Cloudflare's ever-expanding global network - bringing the power and flexibility of a cloud data center, and the redundancy of a massively distributed system, within milliseconds of virtually every Internet user.

"Prior to today, the only way to write code that ran at the edge of Cloudflare's network was to be a Cloudflare employee. Cloudflare Workers opens the scale of our global network to any developer," explained Matthew Prince, co-founder and CEO of Cloudflare. "By bridging the front-end and back-end with a third place to develop code, we're excited Cloudflare Workers will empower a new class of applications that were previously impossible. I can't wait to see what developers build."

The benefits of Cloudflare Workers include:

  • Programmable: Developers can deploy custom JavaScript code at the edge to intelligently respond to users on any browser or API client.
  • Scalable: Cloudflare Workers runs across Cloudflare's 127+ data centers and dynamically scales to meet the demands of any load.
  • Fast: Cloudflare's global network is within milliseconds of virtually every Internet user, allowing Cloudflare Workers to support latency-sensitive applications.
  • Resilient: A globally-distributed, "serverless" architecture ensures that Cloudflare Workers is not hamstrung by any single point of failure.
  • Unconstrained: Support for complex computing tasks without worrying about end users' bandwidth or battery burden.
  • Affordable: Cloudflare Workers is priced at 50¢ per 1 million tasks, making its pricing easy to understand, globally consistent, predictable, and less expensive than centralized alternatives.
  • Portable: Powered by JavaScript, the Internet's most popular programming language, Cloudflare Workers supports the same code that many developers have already used for their front- and back-end applications.
  • Updatable: Developers can push updates to Cloudflare Workers and within seconds know their code has been deployed globally - without having to wait for end users to update their apps or centralized cloud platforms that can take half an hour or more to deploy code.
  • Backward Compatible: Legacy static configuration languages like Varnish Configuration Language (VCL) or Edge Side Includes (ESI) can be automatically converted to dynamic Cloudflare Workers.

Cloudflare announced the Cloudflare Workers beta in September. Since then, customers in the beta have run billions of edge computing tasks using Cloudflare Workers.

"Cloudflare Workers saves us a great deal of time," said John Thompson, Senior System Administrator at MaxMind. "Managing bot traffic without Workers would consume valuable development and server resources that are better spent elsewhere."

"At Postmates, customer trust is the most important thing," said Aabhas Sharma, Infrastructure Lead at Postmates. "We needed a way to do a high volume of redirects without dedicating additional internal resources. Ultimately, Cloudflare Workers gave us a simpler way to build flexibility and fine-grained control into our systems at the edge for a more reliable and secure process."

"Moving away from VCL and adopting Cloudflare Workers will allow us to do some creative routing that will let us deliver JavaScript to npm's millions of users even faster than we do now," said CJ Silverio, CTO of npm, Inc. "We will be building our next generation of services on Cloudflare's platform and we get to do it in JavaScript!"

The uses cases for Cloudflare Workers are emerging across a variety of verticals:

  • An adtech beta customer is using Workers to run real-time tests to determine which advertisement versions yield the best conversions. They have benefitted from higher conversions for their customers and increased revenue as a company, all while bringing previously high-priced ad optimization capabilities to a broader market.
  • Another customer in media and publishing uses Workers to redirect language-specific readers to the German version of their site, providing a more personalized experience and an opportunity to build an optimized advertising base.
  • An eCommerce customer uses Workers to identify the type of device users are connecting from so that they can optimally deliver images. This results in a better user experience and ultimately more purchases.
  • A gaming company is now using Workers to perform authentication and redirects to their back-end infrastructure. Workers has transformed their operational and capex expenditures by eliminating additional server hardware that hosts NGINX, saving countless hours of engineering time.

To learn more about Cloudflare Workers, please check out the resources below.

About Cloudflare
Cloudflare, Inc. (www.cloudflare.com / @cloudflare) is on a mission to help build a better Internet. Today the company runs one of the world's largest networks that powers more than 10 trillion requests per month, which is nearly 10 percent of all Internet requests for more than 2.5 billion people worldwide. Cloudflare protects and accelerates any Internet application online without adding hardware, installing software, or changing a line of code. Internet properties powered by Cloudflare have all web traffic routed through its intelligent global network, which gets smarter with each new site added. As a result, they see significant improvement in performance and a decrease in spam and other attacks. Cloudflare was recognized by the World Economic Forum as a Technology Pioneer, named the Most Innovative Network & Internet Technology Company for two years running by the Wall Street Journal, and ranked among the world's 50 most innovative companies by Fast Company. Headquartered in San Francisco, CA, Cloudflare has offices in Austin, TX, Champaign, IL, New York, NY, Washington, DC, London, and Singapore.

Contact:
Daniella Vallurupalli
Communications
daniella@cloudflare.com 
press@cloudflare.com 
650-483-4463




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cloudflare, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum